RPAM
CYTK icon

Rhenman & Partners Asset Management’s Cytokinetics CYTK Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,375
Closed -$2.82M – 93
2025
Q4 		$2.82M Sell
44,375
-210,875
-83% -$13.1M 0.26% 82
2025
Q3 		$14M Buy
255,250
+151,000
+145% +$6.22M 1.55% 26
2025
Q2 		$3.44M Hold
104,250
– – 0.44% 60
2025
Q1 		$4.19M Sell
104,250
-45,000
-30% -$2.07M 0.48% 50
2024
Q4 		$7.02M Sell
149,250
-31,250
-17% -$1.62M 0.72% 48
2024
Q3 		$9.53M Sell
180,500
-17,015
-9% -$948K 0.77% 45
2024
Q2 		$10.7M Hold
197,515
– – 1.03% 35
2024
Q1 		$13.8M Buy
197,515
+47,603
+32% +$3.68M 1.31% 29
2023
Q4 		$12.5M Sell
149,912
-50,088
-25% -$1.81M 1.25% 30
2023
Q3 		$5.89M Hold
200,000
– – 0.64% 46
2023
Q2 		$6.52M Sell
200,000
-5,000
-2% -$185K 0.69% 48
2023
Q1 		$7.01M Sell
205,000
-11,322
-5% -$462K 0.77% 42
2022
Q4 		$9.91M Buy
216,322
+6,322
+3% +$272K 1.03% 37
2022
Q3 		$9.17M Sell
210,000
-20,000
-9% -$963K 0.96% 39
2022
Q2 		$9.04M Sell
230,000
-65,000
-22% -$2.62M 1.03% 38
2022
Q1 		$10.9M Buy
295,000
+145,000
+97% +$5.15M 1.07% 38
2021
Q4 		$6.84M Buy
+150,000
New +$5.79M 0.45% 62

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rhenman & Partners Asset Management's CYTK Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 44,375 shares — an estimated $2.82M sold.

Rhenman & Partners Asset Management first reported a position in CYTK in Q4 2021 and held it in 17 quarters. The position peaked at $14M in Q3 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Rhenman & Partners Asset Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 44,375 Cytokinetics shares in Q1 2026, an estimated $2.82M.
  • Rhenman & Partners Asset Management first reported a position in Cytokinetics in Q4 2021 and held it in 17 quarters.
  • Rhenman & Partners Asset Management's Cytokinetics position peaked at $14M in Q3 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.